- Home
- ICCM vs ASRT Comparison
ICCM vs ASRT Comparison
Compare ICCM & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- ASRT
- Stock Information
- Founded
- ICCM 2006
- ASRT 1995
- Country
- ICCM Israel
- ASRT United States
- Employees
- ICCM N/A
- ASRT N/A
- Industry
- ICCM
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- ASRT Health Care
- Exchange
- ICCM Nasdaq
- ASRT Nasdaq
- Market Cap
- ICCM 61.0M
- ASRT 57.9M
- IPO Year
- ICCM N/A
- ASRT 1997
- Fundamental
- Price
- ICCM $1.05
- ASRT $0.66
- Analyst Decision
- ICCM Strong Buy
- ASRT Strong Buy
- Analyst Count
- ICCM 1
- ASRT 2
- Target Price
- ICCM $2.50
- ASRT $3.25
- AVG Volume (30 Days)
- ICCM 254.9K
- ASRT 265.7K
- Earning Date
- ICCM 05-28-2025
- ASRT 05-12-2025
- Dividend Yield
- ICCM N/A
- ASRT N/A
- EPS Growth
- ICCM N/A
- ASRT N/A
- EPS
- ICCM N/A
- ASRT N/A
- Revenue
- ICCM $3,273,000.00
- ASRT $119,001,000.00
- Revenue This Year
- ICCM $85.75
- ASRT N/A
- Revenue Next Year
- ICCM $189.92
- ASRT $11.71
- P/E Ratio
- ICCM N/A
- ASRT N/A
- Revenue Growth
- ICCM 0.34
- ASRT N/A
- 52 Week Low
- ICCM $0.48
- ASRT $0.51
- 52 Week High
- ICCM $1.66
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- ICCM 46.97
- ASRT 48.85
- Support Level
- ICCM $0.99
- ASRT $0.67
- Resistance Level
- ICCM $1.14
- ASRT $0.71
- Average True Range (ATR)
- ICCM 0.07
- ASRT 0.04
- MACD
- ICCM 0.01
- ASRT 0.00
- Stochastic Oscillator
- ICCM 64.00
- ASRT 47.88
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.